Patients enrolled in EU Phase III Clinical Development Progam to evaluate ATX-101 for Reduction...
Bayer HealthCare’s dermatology business Intendis and KYTHERA Biopharmaceuticals, Inc. announced the initiation of two European...
VistaGen Therapeutics Announces Successful Completion of Initial Phase 1 Safety Study of AV-101
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today...
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Gilead Sciences, Inc.announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of...
Genentech Phase II study shows Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate...
Genentech, a member of the Roche Group announced results from the NEOSPHERE trial, a Phase...
Novartis study shows drug Afinitor plus hormonal therapy delays disease progression in advanced...
A new study shows that the addition of everolimus (Afinitor® tablets) to the hormonal therapy...
Phase III study showed Rituxan/MabThera decreased the risk of needing later treatment with chemotherapy...
Roche announced positive data from a Phase III study of Rituxan/MabThera (rituximab) in patients with...
QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer...
QR Pharma, Inc., a developer of novel drugs to treat Alzheimer's disease (AD), announced...
Bayer and Regeneron Report Positive Top-Line Results of Two Phase 3 Studies
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. announced that in two parallel Phase 3 studies in...
Reata and Abbott Announce Positive Phase 2b Study Results for Bardoxolone Methyl
Abbott Park, Illinois-Reata Pharmaceuticals and Abbott today announced data from a Phase 2b study which...
Novartis discontinues ASA404 clinical trial program and shifts focus to other cancer compounds in...
Novartis announced that the clinical trial program for the investigational cancer treatment ASA404 (vadimezan) will...